Philippe Rinaudo
YOU?
Author Swipe
View article: EO2463 (EO) peptide immunotherapy in patients (pts) with newly diagnosed asymptomatic follicular lymphoma (FL) and marginal zone lymphoma (MZL): Study EONHL1-20/sidney (NCT04669171) primary endpoint lugano objective response analysis
EO2463 (EO) peptide immunotherapy in patients (pts) with newly diagnosed asymptomatic follicular lymphoma (FL) and marginal zone lymphoma (MZL): Study EONHL1-20/sidney (NCT04669171) primary endpoint lugano objective response analysis Open
Background Watchful waiting is a common option for pts with asymptomatic FL/MZL. Anti-tumor immunization may delay or even avoid subsequent need for more toxic therapies. EO is designed from non-self-protein sequences derived from gut bact…
View article: CTIM-15. EO2401 PEPTIDE IMMUNOTHERAPY + NIVOLUMAB +/- BEVACIZUMAB IN FIRST RECURRENT GLIOBLASTOMA: TREATMENT STRATEGY OPTIMIZATION IN THE PHASE 1/2 STUDY EOGBM1-18 / ROSALIE (NCT04116658)
CTIM-15. EO2401 PEPTIDE IMMUNOTHERAPY + NIVOLUMAB +/- BEVACIZUMAB IN FIRST RECURRENT GLIOBLASTOMA: TREATMENT STRATEGY OPTIMIZATION IN THE PHASE 1/2 STUDY EOGBM1-18 / ROSALIE (NCT04116658) Open
EO2401, composed of peptide sequences from gut bacteria that cross-react with glioblastoma tumor-associated antigens (IL13Rα2, BIRC5/survivin, and FOXM1) plus a helper peptide, was administered to HLA-A2 positive patients with first progre…
View article: Combination of acamprosate and baclofen (PXT864) as a potential new therapy for amyotrophic lateral sclerosis
Combination of acamprosate and baclofen (PXT864) as a potential new therapy for amyotrophic lateral sclerosis Open
There is currently no therapy impacting the course of amyotrophic lateral sclerosis (ALS). The only approved treatments are riluzole and edaravone, but their efficacy is modest and short‐lasting, highlighting the need for innovative therap…
View article: Author response for "Combination of acamprosate and baclofen (PXT864) as a potential new therapy for amyotrophic lateral sclerosis"
Author response for "Combination of acamprosate and baclofen (PXT864) as a potential new therapy for amyotrophic lateral sclerosis" Open
View article: Synergistic PXT3003 therapy uncouples neuromuscular function from dysmyelination in male Charcot–Marie–Tooth disease type 1A (CMT1A) rats
Synergistic PXT3003 therapy uncouples neuromuscular function from dysmyelination in male Charcot–Marie–Tooth disease type 1A (CMT1A) rats Open
Charcot–Marie–Tooth disease 1 A (CMT1A) is caused by an intrachromosomal duplication of the gene encoding for PMP22 leading to peripheral nerve dysmyelination, axonal loss, and progressive muscle weakness. No therapy is available. PXT3003 …
View article: Author response for "Combination of acamprosate and baclofen (PXT864) as a potential new therapy for amyotrophic lateral sclerosis"
Author response for "Combination of acamprosate and baclofen (PXT864) as a potential new therapy for amyotrophic lateral sclerosis" Open
View article: Author response for "Synergistic PXT3003 therapy uncouples neuromuscular function from dysmyelination in male Charcot-Marie-Tooth disease type 1A (CMT1A) rats"
Author response for "Synergistic PXT3003 therapy uncouples neuromuscular function from dysmyelination in male Charcot-Marie-Tooth disease type 1A (CMT1A) rats" Open
View article: Author response for "Synergistic PXT3003 therapy uncouples neuromuscular function from dysmyelination in male Charcot-Marie-Tooth disease type 1A (CMT1A) rats"
Author response for "Synergistic PXT3003 therapy uncouples neuromuscular function from dysmyelination in male Charcot-Marie-Tooth disease type 1A (CMT1A) rats" Open
View article: Next-generation drug repurposing using human genetics and network biology
Next-generation drug repurposing using human genetics and network biology Open
Drug repurposing has attracted increased attention, especially in the context of drug discovery rates that remain too low despite a recent wave of approvals for biological therapeutics (e.g. gene therapy). These new biological entities-bas…
View article: biosigner: A New Method for the Discovery of Significant Molecular Signatures from Omics Data
biosigner: A New Method for the Discovery of Significant Molecular Signatures from Omics Data Open
High-throughput technologies such as transcriptomics, proteomics, and metabolomics show great promise for the discovery of biomarkers for diagnosis and prognosis. Selection of the most promising candidates between the initial untargeted st…
View article: Homology modeling of complex structural RNAs
Homology modeling of complex structural RNAs Open
National audience